跳至主要内容
临床试验/NCT05869968
NCT05869968招募中不适用

Biomarkers of Immune Dysfunction and Vaccine Responsiveness in People With Chronic Traumatic Spinal Cord Injury

Northwell Health1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2023年3月31日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
140
试验地点
1
主要终点
mRNA transcript levels for genes expressed according to white blood cell type after flu vaccination

研究概览

简要总结

The purpose of this observational research study is to better understand immune responses to vaccines against viruses (influenza or SARS-CoV2). The goal is to determine any differences in immune responses to vaccines in uninjured people and in people living with spinal cord injuries, who are typically at increased risk of infections.

详细描述

The purpose of this research study is to measure a person's immune response to a vaccine by measuring types of circulating white blood cells (WBC) and the substances they produce in blood, including antibodies, proteins, and ribonucleic acids (the body's genetic blueprint for making proteins).

The research will study two populations: uninjured people and people living with spinal cord injury (SCI), who are often at increased risk of infections. We will measure and observe over time any differences in immune responses to vaccines between those groups or among people with SCI according to their injury severity or level.

The overall goal of this study is to increase knowledge of immune responses to vaccination against influenza virus that causes the flu, and to the SARS-CoV-2 virus that causes COVID-19. There is currently a lack of information about what influences individual responses to vaccines and why people with SCI are at typically at increased risk of infection. Results from this study may teach us how to improve vaccination strategies and other ways to fight infections in uninjured people and in people with SCI

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 89 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • To be eligible for prospective enrollment, participants are required to meet the following inclusion criteria:
  • 18-89 years old with traumatic SCI
  • initial traumatic SCI >/=1 year from enrollment (DOD funded study)
  • initial traumatic SCI <1 year from enrollment (non-DOD funded pilot study)
  • American Spinal Injury Association (ASIA) classification grade A-D
  • Neurological Injury Level C1-T10
  • Demonstrate capacity to provide informed consent using the "teach back" method to verify understanding and appreciation of study objectives and procedures.
  • Exclusion Criteria
  • To be eligible for prospective enrollment, SCI participants are required to not meet the following exclusion criteria:
  • Stage III-IV pressure ulcers
  • Cancer, chemotherapy, neutropenia
  • Pregnancy or lactation
  • No known SCI
  • Autoimmune disease
  • Pre-existing neurological disease
  • History of dementia
  • Any other condition that would compromise their ability to provide informed consent
  • Any other condition that a study physician feels would preclude participation or be contraindicated
  • Uninjured Control Group:
  • Inclusion Criteria
  • Uninjured Control Participant Inclusion Criteria: To be eligible for prospective enrollment, participants are required to meet the following inclusion criteria:
  • 18-89 years old without traumatic SCI
  • Demonstrate capacity to provide informed consent using the "teach back" method to verify understanding and appreciation of study objectives and procedures.
  • Exclusion Criteria
  • To be eligible for prospective enrollment, uninjured control participants are required to not meet the following exclusion criteria:
  • Cancer, chemotherapy, neutropenia
  • Pregnancy or lactation
  • Autoimmune disease
  • Pre-existing neurological disease
  • History of dementia
  • Any other condition that would compromise their ability to provide informed consent
  • Any other condition that a study physician feels would preclude participation or be contraindicated

排除标准

  • 未提供

结局指标

主要结局

mRNA transcript levels for genes expressed according to white blood cell type after flu vaccination

时间窗: 0-28 days after flu vaccination

Serum samples will be used to determine if gene expression levels made by specific types of white blood cells are different between participant groups and within the SCI group by injury level and severity.

Anti-flu antibody titers in response to vaccination

时间窗: 0-28 days after flu vaccination

Serum samples will be used to determine antibody titers for anti-flu antibodies at baseline and after vaccination. These samples will be obtained to determine if vaccine responses are different between participant groups and within the SCI group by injury level and severity

次要结局

  • Systemic inflammatory cytokine levels in response to vaccination(0-28 days after vaccination)
  • Anti-COVID-19 antibody titers in response to vaccination(0-28 days after COVID-19 vaccination)
  • mRNA transcript levels for genes expressed according to white blood cell type after COVID-19 vaccination(0-28 days after COVID-19 vaccination)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ona Bloom

Professor

Northwell Health

研究点 (1)

Loading locations...

相似试验